2011年
Effect of Low-Dose Gemcitabine on Unresectable Pancreatic Cancer in Elderly Patients
DIGESTION
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 84
- 号
- 3
- 開始ページ
- 230
- 終了ページ
- 235
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1159/000330384
- 出版者・発行元
- KARGER
Background/Aims: The efficacy of gemcitabine (GEM) on unresectable pancreatic cancer has been reported. However, in elderly patients, severe toxicities are frequently observed. In this study we aimed to assess the efficacy of low-dose GEM on unresectable pancreatic cancer in elderly patients. Methods: We reviewed 68 elderly patients (6 65 years) with unresectable pancreatic cancer. Thirty-six patients were treated with low-dose GEM (600-800 mg/m(2); GEM group), and the other 32 received best supportive care (BSC group). Results: Median survival was 7.6 and 2.3 months in the GEM and BSC groups, respectively. In the GEM group, the median survival period was longer in 24 patients showing partial response or stable disease than in 12 patients showing progressive disease (11.4 vs. 5.3 months). Furthermore, the patients showing progressive disease had better 6-month survival than patients in the BSC group. Thirteen patients (36%) developed severe toxicities (grade 3 or 4). Low-dose GEM, stage of disease and performance status were associated with the prognosis. Conclusions: Low-dose GEM may improve the prognosis of elderly patients with un-resectable pancreatic cancer. Furthermore, frequencies of severe toxicity seem lower in patients treated with low-dose GEM compared with previous reports. Copyright (C) 2011 S. Karger AG, Basel
- リンク情報
- ID情報
-
- DOI : 10.1159/000330384
- ISSN : 0012-2823
- Web of Science ID : WOS:000295987400009